Press release Revenues at the end of September 2015 Bezons, October 22, 2015 – 5:45pm – RIBER, the global molecular beam epitaxy (MBE) specialist, is reporting €7.7 million in revenues at the end of September 2015. The order book has continued to pick up, climbing to €10.4 million. Business developments Revenues (€M) 2015 2014 Change
Revenues at the end of September 2015
Bezons, October 22, 2015 – 5:45pm
– RIBER, the global molecular beam epitaxy (MBE) specialist, is reporting €7.7 million in revenues at the end of September 2015. The order book has continued to pick up, climbing to €10.4 million.
|Total for 9 months||7.7||9.2||-16%|
|Revenues (€M – at September 30)||2015||2014||Change|
|Services and accessories||2.9||3.1||-8%|
|Cells and sources||1.4||0.7||+99%|
|Total for 9 months||7.7||9.2||-16%|
The billing figures for systems reflect the change in seasonal trends with the production plan, focused on the end of the year in 2015 and the first half of 2016, in line with the orders recorded late. During the third quarter, RIBER billed for just one research machine, compared with three for the same period in 2014.
Sales of cells and sources are up thanks to the delivery of high-capacity linear cells, designed for producing OLED flat screens and intended to equip a pilot line in Korea. Sales of MBE cells have also developed.
At September 30, 2015, the breakdown of RIBER's revenues was as follows: Asia (39%), Europe (35%), North America (10%) and other continents (16% – primarily South Africa and New Zealand).
Change in the order book and outlook
|Order book (€M – at September 30)||2015||2014||Change|
|Services and accessories||2.3||2.4||-4%|
|Cells and sources||0.7||0.8||-8%|
During the third quarter of 2015, RIBER recorded orders for five R&D systems in Europe and Asia. At September 30, 2015, the order book represented €10.4 million, with eight MBE systems, including one production system (€7.5 million, up 53%), as well as orders for services, cells and accessories (€3.0 million, stable year-on-year). On account of the production timeframes involved, deliveries of the systems ordered will run through to 2016.
As Frédérick Goutard, Chairman of the Executive Board, explains:
"The third quarter of 2015 confirms that RIBER's order book is picking up again. This upturn has been driven by the signing of several research contracts and supported by our efforts to further strengthen our range of services and cells. Riber is working to ensure that this turnaround continues over the long term. Alongside this, we are moving forward with the industrial qualification of our new range of OLED cells".
Acknowledging Mr Olivier Handschumacher's upcoming departure, the Supervisory Board has appointed Mr Rino Contini as a member of the Executive Board from November 1, 2015.
Mr Rino Contini, 56, has a doctorate in material sciences from Université d'Aix-Marseille and worked on a post-doctorate basis on a molecular beam epitaxy project at Université d'Aix la Chapelle before joining Riber in 1998, where he held various predominantly sales positions. Since 2015, he has been Riber's commercial director.
Combined general meeting on December 15, 2015 from 10 am
Riber designs and produces molecular beam epitaxy (MBE) systems as well as evaporation sources and cells for the semiconductor industry. This high-technology equipment is essential for the manufacturing of compound semiconductor materials and new materials that are used in numerous consumer applications, from new information technologies to OLED flat screens and new-generation solar cells.
Riber recorded €16.6 million in revenues for 2014, with 96 employees at the end of 2014. The company is ISO9001 certified. Riber is listed on NYSE-Euronext Paris, Compartment "C", and is part of the CAC Small, CAC Mid & Small, CAC Technology and CAC T. HARD. & EQ indices. Riber is one of the best-rated companies in the Gaïa-index, the leading SRI index for French mid-caps. Riber is eligible for SME share-based savings schemes.
ISIN: FR0000075954 – RIB
Bloomberg: RIB: FP
BPI France-approved innovative company
tel: +33 1 39 96 65 00
tel: +33 1 53 65 68 68
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: RIBER via GlobeNewswire